Paraoxonase PON1 polymorphism Leu-Met54 is associated with carotid atherosclerosis: Results of The Austrian Stroke Prevention Study

Stroke

Volumn 29, Issue 10, 1998, Pages 2043-2048

  Schmidt, Helena ^a   Schmidt, Reinhold ^a   Niederkorn, Kurt ^a   Gradert, Anita ^a   Schumacher, Martin ^a   Watzinger, Norbert ^a   Hartung, Hans Peter ^a   Kostner, Gert M ^a  

^a UNIVERSITY OF GRAZ   (Austria)

Author keywords

Atherosclerosis; Carotid arteries; Genetics; Paraoxonase

Indexed keywords

ARGININE; ARYLESTERASE; FIBRINOGEN; GLUTAMINE; LEUCINE; LOW DENSITY LIPOPROTEIN CHOLESTEROL; METHIONINE;

ADULT; AGED; ARTICLE; ATHEROSCLEROSIS; AUSTRIA; CAROTID ARTERY DISEASE; CONTROLLED STUDY; FEMALE; GENETIC POLYMORPHISM; GENOTYPE; HUMAN; ISCHEMIC HEART DISEASE; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; STROKE;

EID: 0031690303     PISSN: 00392499     EISSN: None     Source Type: Journal    
DOI: 10.1161/01.STR.29.10.2043     Document Type: Article

References (39)

1. Yatsu FM. Atherogenesis and stroke. In: Barnett HJM, Mohr JP, Stein BM, Yatsu FM, eds. Pathophysiology, Diagnosis, and Management. New York, NY: Churchill Livingstone; 1986:45-56.
2. Ross R. Atherosclerosis: a defense mechanism gone awry. The Rous-Whipple Award Lecture. Am J Pathol. 1993;143:987-1002.
3. Steinberg D, Parthasarathy S, Carew TE, Khoo JC, Witztum JL. Beyond cholesterol: modification of low-density-lipoprotein that increases its atherogenicity. New Engl J Med. 1989;320:915-924.
4. Chait A, Heinecke JW. Lipoprotein modification: cellular mechanisms. Curr Opin Lipidol. 1994;5:365-370.
5. Parthasarathy S, Barnett J, Fong LJ. High-density lipoprotein inhibits the oxidative modification of low-density lipoprotein. Biochim Biophys Acta. 1990;1044:275-283.
6. Mackness MI, Durrington PN. HDL, its enzymes and its potential to influence lipid peroxidation. Atherosclerosis. 1995;115:243-253.
7. Mackness MI, Mackness B, Durrington PN, Connelly PW, Hegele RA. Paraoxonase: biochemistry, genetics and relationship to plasma lipoproteins. Curr Opin Lipidol. 1996;7:69-76.
8. Mackness MI, Arrol S, Abbott CA, Durrington PN. Protection of low-density lipoprotein against oxidative modification by high-density lipoprotein associated paraoxonase. Atherosclerosis. 1993;104:129-135.
9. Humbert R, Adler DA, Disteche CM, Hassett C, Omiecinski CJ, Furlong CE. The molecular basis of the human serum paraoxonase activity polymorphism. Nat Genet. 1993;3:73-76.
10. Hassett C, Richter RJ, Humbert R, Chapline C, Crabb JW, Omiecinski CJ, Furlong CE. Characterisation of cDNA clones encoding rabbit and human serum paraoxonase: the mature protein retains its signal sequence. Biochemistry. 1991;30:10141-10149.
11. Watson AD, Berliner JA, Hama SY, La Du BN, Faull KF, Fogelman AM, Navab M. Protective effect of high density lipoprotein associated paraoxonase: inhibition of the biological activity of minimally oxidised low density lipoprotein. J Clin Invest. 1995;96:2882-2891.
12. Serrato M, Marian AJ. A variant of human paraoxonase/aryltransferase gene is a risk factor for coronary artery disease. J Clin Invest. 1995; 96:3005-3008.
13. Ruiz J, Blanche H, James RW, Blatter-Garin M-C, Vaisse C, Charpentier G, Cohen N, Morabia A, Passa P, Froguel P. Gln-Arg192 polymorphism of paraoxonase and coronary heart disease in type 2 diabetes. Lancet. 1995;346:869-872.
14. Abbott CA, Mackness MI, Kumar S, Boulton AJ, Durrington PN. Serum paraoxonase activity, concentration, and phenotype distribution in diabetes mellitus and its relationship to serum lipids and lipoproteins. Arterioscler Thromb Vasc Biol. 1995;15:1812-1818.
15. Schmidt R, Lechner H, Fazekas F, Niederkom K, Reinhart B, Grieshofer P, Horner S, Offenbacher H, Koch M, Eber B, Schumacher M, Kapeller P, Freidl W, Dusek T. Assessment of cerebrovascular risk profiles in healthy persons: definition of research goals and the Austrian Stroke Prevention Study. Neuroepidemiology. 1994;13:308-313.
16. Kittner SJ, Sharkness CM, Price TR, Piotnik GD, Dambrosia JM, Wolf PA, Mohr JP, Hier DB, Kase CS, Tuhrim S. Infarcts with a cardiac source of embolism in the NINCDS Stroke Data Bank: historical features. Neurology. 1990;40:281-284.
17. Rose GA. The diagnosis of ischemic heart pain and intermittent claudication in field surveys. Bull WHO. 1962;27:645-658.
18. Blackburn H, Keys A, Simonson E, Rautaharju P, Punsar S. The electrocardiogram in population studies: a classification system. Circulation. 1960;21:1160-1175.
19. Clauss A. Gerinnungsphysiologische Schnellmethode zur Bestimmung des Fibrinogens. Acta Haematol. 1957;17:237-246.
20. 148-→T) is associated with carotid atherosclerosis: results of the Austrian Stroke Prevention Study. Arterioscler Thromb Vasc Biol. 1998;18:487-492.
21. Schmidt R, Schmidt H, Fazekas F, Schumacher M, Niederkorn K, Kapeller P, Weinrauch V, Kostner GM. Apolipoprotein E polymorphism and silent microangiopathy related cerebral damage: results of the Austrian Stroke Prevention Study. Stroke. 1997;28:951-956.
22. Grobbee DE, Bots ML. Carotid artery intima-media thickness as an indicator of generalised atherosclerosis. J Intern Med. 1994;236:551-553.
23. Bots ML, Hoes AW, Koudstal PJ, Hofman A, Grobbee DE. Common carotid intima-media thickness and risk of stroke and myocardial infarction: the Rotterdam Study. Circulation. 1997;96:1432-1437.
24. Blatter-Garin M-C, James RW, Dussoix P, Blanche H, Passa P, Froguel P, Ruiz J. Paraoxonase polymorphism Met-Leu54 is associated with modified serum concentrations of the enzyme: a possible link between the paraoxonase gene and increased risk of cardiovascular disease in diabetes. J Clin Invest. 1997;99:62-66.
25. Sanghera DK, Saha N, Aston CE, Kamboh MI. Genetic polymorphism of paraoxonase and the risk of coronary heart disease. Arterioscler Thromb Vasc Biol. 1997;17:1067-1073.
26. 3. J Biol Chem. 1989;264:6488-6494.
27. Rubin EM, Krauss RM, Spangler EA, Verstuyft JG, Clift SM. Inhibition of early atherogenesis in transgenic mice by human apolipoprotein A1. Nature. 1991;353:265-267.
28. Warden CH, Hedrick CC, Qiao JH, Castellani LW, Lusis AJ. Atherosclerosis in transgenic mice overexpressing apolipoprotein A-II. Science. 1993;261:469-472.
29. Castellani LW, Navab M, Van Lenten BJ, Hedrick CC, Hama SJ, Goto AM, Fogelman AM, Lusis AJ. Overexpression of apolipoprotein All in transgenic mice converts high density lipoproteins to proinflammatory particles. J Clin Invest. 1997;100:464-474.
30. Van Lenten BJ, Hama SY, de Beer FC, Stafforini DM, McIntyre TM, Prescott SM, La Du BN, Fogelman AM, Navab M. Anti-inflammatory HDL becomes pro-inflammatory during acute phase response: loss of protective effect of HDL against LDL oxidation in aortic wall cell culture. J Clin Invest. 1995;96:2758-2767.
31. Navab M, Hama-Levy S, Van Lenten BJ, Fonarow GC, Cardinez CJ, Castellani LW, Brennan ML, Lusis AJ, Fogelman AM. Mildly oxidised LDL induces an increased apolipoprotein J/paraoxonase ratio. J Clin Invest. 1997;99:2005-2019.
32. Mackness B, Hunt R, Durrington PN, Mackness MI. Increased immunolocalization of paraoxonase, clusterin, and apolipoprotein A-I in the human artery wall with progression of atherosclerosis. Arterioscler Thromb Vasc Biol. 1997;17:1233-1238.
33. Mackness MI, Mackness B, Arrol S, Wood G, Bhatnagar D, Durrington PN. Presence of paraoxonase in human interstitial fluid. FEBS Lett. 1997;416:377-380.
34. Mackness MI, Arrol S, Mackness B, Durrington PN. Alloenzymes of paraoxonase and effectiveness of high-density lipoproteins in protecting low-density lipoprotein against lipid peroxidation. Lancet. 1997;349: 851-852.
35. Mackness B, Mackness MI, Arrol S, Turkie W, Durrington PN. Effect of the human serum paraoxonase 55 and 192 genetic polymorphisms on the protection by high density lipoprotein against low density lipoprotein oxidative modification. FEBS Lett. 1998;423:57-60.
36. Leviev I, Negro F, James RW. Two alleles of the human paraoxonase gene produce different amounts of mRNA: an explanation for differences in serum concentrations of paraoxonase associated with the (Leu-Met54) polymorphism. Arterioscler Thromb Vasc Biol. 1997;17:2935-2939.
37. Primo-Parmo SL, Sorenson RC, Teiber J, La Du BN. The human serum paraoxonase/aryltransferase gene (PON1) is one member of a multigene family. Genomics. 1996;33:498-507.
38. Hegele RA, Connelly PW, Scherer SW, Hanley AJ, Harris SB, Tsui LC, Zinman B. Paraoxonase-2 gene (PON2) G148 variant associated with elevated fasting plasma glucose in noninsulin-dependent diabetes mellitus. J Clin Endocrinol Metab. 1997;82:3373-3377.
39. Sanghera DK, Aston CE, Saha N, Kamboh MI. DNA polymorphisms in two paraoxonase genes (PON1 and PON2) are associated with the risk of coronary heart disease. Am J Hum Genet. 1998;62:36-44.